Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients

James R. Hocker, Subrato J. Deb, Min Li, Megan R. Lerner, Stan A. Lightfoot, Aurelien A. Quillet, R. Jane Hanas, Matthew Reinersman, Jess L. Thompson, Nicole T. Vu, Thomas C. Kupiec, Daniel J. Brackett, Marvin D. Peyton, Stephen M. Dubinett, Harold M. Burkhart, Russell G. Postier, Jay S. Hanas

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.

Original languageEnglish (US)
Pages (from-to)573-585
Number of pages13
JournalCancer Investigation
Volume35
Issue number9
DOIs
StatePublished - Oct 21 2017
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients'. Together they form a unique fingerprint.

Cite this